Table 1.
HNSCC patients information and tumor characteristics in the study.
| Information/characteristic | Testing cohort | Training cohort | p-value |
|---|---|---|---|
| Age | 63.57 ± 12.01 (31–87) | 61.18 ± 11.87 (27–86) | 0.18 |
| Sex | 0.74 | ||
| Male | 53 (76.8%) | 108 (78.8%) | |
| Female | 16 (23.2%) | 29 (21.2%) | |
| Tumor primary location | 0.45 | ||
| Oral cavity | 35 (50.7%) | 71 (51.8%) | |
| Oropharynx | 12 (17.4%) | 13 (9.5%) | |
| Hypoharynx | 12 (17.4%) | 28 (20.4%) | |
| Larynx | 10 (14.5%) | 22 (16.1%) | |
| Others | 0 | 3 (2.2%) | |
| Tumor differentiation | 0.95 | ||
| WD | 42 (60.9%) | 84 (61.3%) | |
| MD/PD | 27 (39.1%) | 53 (38.7%) | |
| T classification | 0.64 | ||
| T1–2 | 19 (27.5%) | 42 (30.7%) | |
| T3–4 | 50 (72.5%) | 95 (69.3%) | |
| N classification | 0.52 | ||
| N0 | 38 (55.1%) | 69 (51.1%) | |
| N+ | 31 (44.9%) | 68 (48.9%) | |
| Stage | 0.79 | ||
| I–II | 14 (20.3%) | 30 (21.9%) | |
| III–IV | 55 (79.7%) | 107 (78.1%) | |
| Enhancement types | |||
| Observer 1 | 0.70 | ||
| Homogeneous 1 | 23 (33.3%) | 42 (30.7%) | |
| Heterogeneous 1 | 46 (66.7%) | 95 (69.3%) | |
| Observer 2 | 0.23 | ||
| Homogeneous 2 | 22 (31.9%) | 33 (24.1%) | |
| Heterogeneous 2 | 47 (68.1%) | 104 (75.9%) |
Age data are mean ± standard deviation, age range in parentheses, other data are number (percentage). P > 0.05.